taprostene and Arteriosclerosis

taprostene has been researched along with Arteriosclerosis* in 1 studies

Trials

1 trial(s) available for taprostene and Arteriosclerosis

Article	Year
In vivo modulation of platelet deposition on human atherosclerotic lesions by various antiaggregatory prostaglandins. Folia haematologica (Leipzig, Germany : 1928), 1988, Volume: 115, Issue:4 The influence of intravenous infusions of various prostaglandins on in vivo platelet function was studied after labelling of autologous platelets with 100 mu ci 111 indium-oxinesulfate in patients with peripheral vascular disease stage II according to FONTAINE. PGI2 (5 ng/kg/min) provoked a significant decrease of platelet deposition and a prolongation in platelet half-life time (74 +/- 6 vs 68 +/- 5 hours). PGE1 (25 ng/kg/min) failed to influence platelet deposition, but prolonged significantly platelet half-life time (82 +/- 6 vs 76 +/- 8 hours). CG 4203 (25 ng/kg/min) decreased significantly platelet deposition and prolonged significantly platelet half-life time (73 +/- 10 vs 67 +/- 11 hours). Iloprost (1 and 2 ng/kg/min) reduced significantly platelet deposition without dose relation. Half-life time was increased significantly after therapy compared to placebo (1 ng: 76 +/- 7 vs 69 +/- 7; 2 ng: 73 +/- 9 vs 67 +/- 9 hours). Topics: Aged; Alprostadil; Arteriosclerosis; Cardiovascular Agents; Epoprostenol; Humans; Iloprost; Male; Middle Aged; Platelet Aggregation Inhibitors	1988

Article

Year

In vivo modulation of platelet deposition on human atherosclerotic lesions by various antiaggregatory prostaglandins.

Folia haematologica (Leipzig, Germany : 1928), 1988, Volume: 115, Issue:4

The influence of intravenous infusions of various prostaglandins on in vivo platelet function was studied after labelling of autologous platelets with 100 mu ci 111 indium-oxinesulfate in patients with peripheral vascular disease stage II according to FONTAINE. PGI2 (5 ng/kg/min) provoked a significant decrease of platelet deposition and a prolongation in platelet half-life time (74 +/- 6 vs 68 +/- 5 hours). PGE1 (25 ng/kg/min) failed to influence platelet deposition, but prolonged significantly platelet half-life time (82 +/- 6 vs 76 +/- 8 hours). CG 4203 (25 ng/kg/min) decreased significantly platelet deposition and prolonged significantly platelet half-life time (73 +/- 10 vs 67 +/- 11 hours). Iloprost (1 and 2 ng/kg/min) reduced significantly platelet deposition without dose relation. Half-life time was increased significantly after therapy compared to placebo (1 ng: 76 +/- 7 vs 69 +/- 7; 2 ng: 73 +/- 9 vs 67 +/- 9 hours).

Topics: Aged; Alprostadil; Arteriosclerosis; Cardiovascular Agents; Epoprostenol; Humans; Iloprost; Male; Middle Aged; Platelet Aggregation Inhibitors

1988